All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How can serial MRD monitoring be utilized to improve relapse outcomes?

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub was pleased to speak to Nicholas Short, MD Anderson Cancer Centre, US. We asked, How can serial minimal residual disease (MRD) monitoring be utilized to improve relapse outcomes?

How can serial MRD monitoring be utilized to improve relapse outcomes?

Short discusses the prognostic value of MRD and the impact of MRD recurrence in patients with acute myeloid leukemia who have previously achieved MRD-negative remission. This is followed by a discussion of the clinical rarity of detecting MRD recurrence and the poor outcomes seen in these patients compared with those with persistent MRD negativity. Short concludes by describing the benefit of serial monitoring of MRD to identify these high-risk patients.